Results for biosimilar translation from English to Maltese

abseamed is a ‘biosimilar’ medicine.
abseamed huwa mediċina ‘bijosimili’.

‘inflectra is a ‘biosimilar’ medicine.
‘inflectra huwa mediċina ‘bijosimili’.

abasaglar is a biosimilar medicinal product.
abasaglar hu prodott mediċinali bijosimili.

filgrastim hexal is a ‘biosimilar’ medicine.
filgrastim hexal huwa mediċina ‘bijosimili’.

epoetin alfa hexal is a ‘biosimilar’ medicine.
epoetin alfa hexal huwa mediċina ‘bijosimili’.

benepali contains the active substance etanercept and is a ‘biosimilar medicine’.
benepali fih is-sustanza attiva etanercept u huwa ‘mediċina bijosimili’.

for more information on biosimilar medicines, see the question-and-answer document here.
għal aktar informazzjoni dwar il- mediċini bijosimili, ara d-dokument ta' mistoqsija u tweġiba hawn.

accofil, which contains the active substance filgrastim, is a ‘biosimilar medicine’.
accofil, li fih is-sustanza attiva filgrastim, huwa ‘mediċina bijoloġika simili’.

at this point in time, the chmp was of the opinion that alpheon could not be considered as a biosimilar medicine of roferon-a, the reference medicinal product.
f’ dan iż- żmien, il- chmp kien ta ’ l- opinjoni li alpheon ma setax jiġi kkunsidrat bħala mediċina bijosimili ta ’ roferon- a, il- prodott mediċinali ta ’ referenza.

the agency will implement a number of adopted guidelines relating to similar biological (biosimilar) medicinal products, and will consolidate procedures for generic medicines.
l- aġenzija ser timplimenta għadd ta 'linji gwida adottati relatati ma' prodotti bijoloġiċi simili (bijosimili), u ser tikkonsolida l- proċeduri għal mediċini ġeneriċi.

bemfola is a biosimilar medicinal product, i.e. a medicine that has been demonstrated to be similar in quality, safety and efficacy to the reference medicinal product gonal-f.
bemfola huwa prodott mediċinali biosimili, jiġifieri huwa mediċina li ntweriet li hija simili fil- kwalità, is-sigurtà u l-effikaċja tal-prodott mediċinali ta’ referenza gonal-f.

3) the off-patent market (generics and biosimilars) – where, as market exclusivity for medicines expires, competitor products generate price erosion and therefore savings for healthcare systems that can be used to fund newer medicines.
3) is-suq mhux imħares bi privattivi (ġeneriċi u bijosimili) – fejn, meta l-esklużività tas-suq għall-mediċini tiskadi, il-prodotti kompetituri jiġġeneraw erożjoni tal-prezzijiet u għaldaqstant iffrankar għas-sistemi tal-kura tas-saħħa li jistgħu jintużaw għall-finanzjament ta’ mediċini aktar ġodda.